Von Willebrand Disease Clinical Trials

68 clinical trials for Von Willebrand Disease across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB — RECRUITING · PHASE2
• A Study Assessing HMB-002 in Participants With Von Willebrand Disease — RECRUITING · PHASE1
• A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease — RECRUITING · PHASE2
• A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) — RECRUITING · PHASE3
• Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease — RECRUITING · NA
• A Study of Bleeding and Treatment in Participants With Von Willebrand Disease — RECRUITING
• Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) — RECRUITING · PHASE3
• An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD) — RECRUITING
• Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects — RECRUITING
• A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) — RECRUITING · PHASE3
• A PHASE III, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH TYPE 3 VON WILLEBRAND DISEASE — RECRUITING · PHASE3
• A SAFETY, TOLERABILITY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF VGA039 FOLLOWING INTRAVENOUS OR SUBCUTANEOUS ADMINISTRATION OF SINGLE ASCENDING DOSES IN HEALTHY ADULTS AND ADULT PATIENTS WITH VON WILLEBRAND DISEASE — RECRUITING
• Clinical study to assess how well wilate works in the regular treatment of young children with severe von Willebrand disease — ACTIVE_NOT_RECRUITING · PHASE3
• EFFICACY AND SAFETY STUDY OF vWF SD-35-DH (WILFACTIN) IN PATIENTS UNDER LONG TERM PROPHYLAXIS — COMPLETED · PHASE4
• Efficacy and safety study of vWF SD-35-DH (WILFACTIN) in children under 6 years of age — COMPLETED · PHASE3
• A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6) — TERMINATED · PHASE3
• Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease — WITHDRAWN · PHASE4
• A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) — COMPLETED · PHASE3
• The Bleeding Assessment Tool (BAT) — ACTIVE_NOT_RECRUITING
• A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK) — COMPLETED
• Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age — COMPLETED · PHASE3
• Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate — NOT_YET_RECRUITING
• A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE 3 CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROPHYLACTIC VGA039 IN ADOLESCENT AND ADULT PATIENTS WITH VON WILLEBRAND DISEASE — NOT_YET_RECRUITING · PHASE3
• Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD) — OTHER
• A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) — COMPLETED · PHASE3
• T-TAS® wS Method Comparison — COMPLETED
• Molecular and Clinical Profile of Von Willebrand Disease in Spain — COMPLETED
• Registry of Patients With Von WilLEbrand Disease Treated With Voncento® — COMPLETED
• A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers — COMPLETED
• A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi — COMPLETED
• Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients — ACTIVE_NOT_RECRUITING · PHASE4
• A PHASE 3, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE — NOT_YET_RECRUITING · PHASE3
• CLINICAL STUDY TO INVESTIGATE THE EFFICACY, PHARMACOKINETICS, IMMUNOGENICITY AND SAFETY OF WILATE IN SEVERE VON WILLEBRAND DISEASE PATIENTS UNDER THE AGE OF 6 YEARS — NOT_YET_RECRUITING
• Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding — COMPLETED
• rVWF IN PROPHYLAXIS — COMPLETED · PHASE3
• Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) — COMPLETED · PHASE3
• Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery — COMPLETED · PHASE3
• Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease — COMPLETED · PHASE1
• Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease — COMPLETED
• Von Willebrand Disease in the Netherlands — OTHER
• Latin-American Von Willebrand Disease Registry — OTHER
• A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) — NOT_YET_RECRUITING · PHASE3
• IL-11 in Adults With Von Willebrand Disease Undergoing Surgery — TERMINATED · PHASE2
• Willebrand International Non-interventional Global Surveillance — COMPLETED
• Study of Voncento® in Subjects With Von Willebrand Disease — COMPLETED · PHASE4
• A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A. — COMPLETED · PHASE3
• IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia — COMPLETED · PHASE2
• The Effect of the Nutraceutical "Hemofix" on the Coagulation System — WITHDRAWN · NA
• The Von Willebrand Disease (VWD) International Prophylaxis Study — COMPLETED
• Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease — COMPLETED · PHASE2

Refine this search